Furthermore, very recently, the addition of the PD-L1 inhibitor avelumab to axitinib has been shown to be beneficial in ACC of the head and neck [36], leading to its inclusion as a therapeutic option for ACC in the National Comprehensive Cancer Network guidelines. Here, CD274 is linked to adrenal cortex carcinoma.